Viridian Therapeutics (VRDN) – Research Analysts’ Weekly Ratings Updates
Several analysts have recently updated their ratings and price targets for Viridian Therapeutics (NASDAQ: VRDN): 4/8/2026 – Viridian Therapeutics had its price target lowered by Wedbush from $37.00 to $31.00. They now have an “outperform” rating on the stock. 4/7/2026 – Viridian Therapeutics had its price target lowered by The Goldman Sachs Group, Inc. from […]
17 Apr 10:08 · The Cerbat Gem